

Requirements for Institutional Biosafety Committees under the *NIH Guidelines*

Aaron Severson, CSU IBC Chair
October 28, 2020



Today's Agenda

- NIH Slides: Introduction to IBC Requirements and duties
- IBCs and IACUCs
- How to apply to CSU's new IBC
- Who needs to apply for IBC approval?
- Intro to the NIH Guidelines and Exemptions to IBC Approval
- Specific details about mouse work

Institutional Biosafety Committees


Established under the *NIH Guidelines* specifically for the review of research involving recombinant or synthetic nucleic acid molecules






History of IBCs

- 1975: The Asilomar Conference established guidelines for research using recombinant nucleic acids
- 1976: The first *NIH Guidelines* were drafted & the Recombinant DNA Advisory Committee (RAC) was formed
- 1978: Review responsibilities were delegated to local IBCs at research establishments
- NIH funding is contingent on compliance with the *Guidelines*




IBC Registration Trends

Number of IBCs registered with OBA




IBCs Registered with NIH



March 2014 = 863




IBCs and NIH - Partners in Oversight



Institutional Biosafety Committees

- IBCs are typically assigned additional review responsibilities
 - Select agents and toxins
 - Blood borne pathogens
 - Xenotransplantation
 - Stem cell research
 - “Dual Use” research
 - Nanotechnology
- Broader purview is a matter of institutional discretion





Assembling an IBC

■ Membership

- At least five individuals
- Appropriate recombinant and synthetic nucleic acid expertise collectively
- Plant and animal experts, biosafety officer as appropriate
- At least two members not affiliated with the institution



Assembling an IBC

- Expertise
 - Expertise in assessment of risk to environment and public health
 - Knowledge of institutional commitments and policies, applicable law, professional standards, community attitudes, and environment
 - Biological safety and physical containment
 - Laboratory technical staff (recommended)



CSU's IBC Membership

Aaron Severson (BGES), Chair

Andy Resnick (Physics)

Bibo Li (BGES)

Moo-Yeal Lee (Chem. Biomed. Eng)

Vania De Paoli (Chemistry)

Lou Turchyn (Animal Facility Mgr.)

Michele Zinner (BGES Lab Mgr.)

Dave Diggins (EHS)

Heidi Page (CWRU EHS Dir.)

Richard London (TriC Biology)

Nneha Sakre (LRI)



Assembling an IBC

- Biological Safety Officer (BSO)
 - A BSO must be appointed and be a member of the IBC if the institution conducts recombinant or synthetic nucleic acid research at:
 - Large scale (>10 L)
 - High containment (BL-3 or BL-4)



Ad hoc Consultants

- Use when reviewing research outside the expertise of your members.



Registering an IBC

- Register the IBC with OBA and file annual membership updates
 - A roster of IBC members
 - Clearly indicate chair, contact person, and special expertise as appropriate (BSO, animal, plant, human gene transfer)
 - Biographical sketches of all members




Registering an IBC

- Purpose of registration and annual updates
 - Provides assurance of local review of biosafety risks
 - Allows OBA to see that IBC expertise is consistent with the *NIH Guidelines*
 - Indicates institutional point of contact
 - Provides census of the field: where research subject to the *NIH Guidelines* is being conducted

IBC Responsibilities

- In a nutshell, what must IBCs review?
 - Research involving recombinant or synthetic nucleic acid molecules for conformity with the *NIH Guidelines*
 - Potential risk to environment and public health
 - Containment levels per *NIH Guidelines*
 - Adequacy of facilities, SOPs, PI and lab personnel training
 - Institutional and investigator compliance; e.g., incident reports





IBC Responsibilities

- In basic and preclinical research, IBCs have authority to:
 - Lower containment levels for certain experiments in which nucleic acid from Risk Group 2-4 is cloned in non-pathogenic organisms
 - Set containment levels for experiments involving whole plants and animals
 - Review periodically institutional compliance with *NIH Guidelines*
 - Adopt emergency plans covering spills, contamination, other accidents




IBC Responsibilities

- For human gene transfer research, IBCs must also ensure:
 - No participant enrolled in a trial until RAC review, IBC and IRB approval has been obtained
 - Issues raised by the RAC in public review are considered
 - Final IBC approval occurs only after RAC review
 - PI compliance with surveillance, data reporting, and adverse event reporting



IBC Responsibilities

- Incident reporting:
 - IBCs must report to the NIH "...any significant problems, violations of the *NIH Guidelines*, or any significant research-related accidents and illnesses"
 - Escaped transgenic animals
 - Needle stick
 - Spills of materials requiring BL2 containment resulting in overt exposure
 - Spills of materials requiring BL3-4 containment resulting in overt or potential exposure



IBCs and Exempt Research


- Should IBCs determine what research is exempt?
Should the PI?
 - A matter of institutional policy
 - IBC may wish to designate the chair, a member, or the BSO to conduct an initial review to confirm what is exempt and what requires full IBC review
 - NIH OBA can help with determinations



IBCs and Exempt Research

- Who determines whether research is exempt at CSU?
 - PIs may read and interpret the *NIH Guidelines* to determine exemption status
 - PIs should consult with IBC if they are uncertain
 - When in doubt, *ASK*. If the IBC doesn't know the answer, we can look it up or ask NIH OBA for guidance.

IBCs and Other Institutional Research Oversight Committees




CSU IBC currently anticipates little overlap with IRB purview, some with IACUC



IBC Coordination with Other Institutional Oversight Committees

- Not prescribed in the *NIH Guidelines*
- Institutions should determine the best way for these committees to interact and share information
- Case IACUC will not review protocols w/ recombinant DNA unless IBC has already approved
- CSU IACUC can contact IBC if any questions on relevant applications



IBCs and IACUCs – Oversight of Animal Research

- Joint purview, and ideally collaborative review, over certain types of research
 - Transgenic or cloned animals
 - Use of recombinant or synthetic nucleic acid molecules in animals
 - Pre-clinical studies and data assessment for human gene transfer protocols



IBC and IACUC Review of Animal Research Subject to the *NIH Guidelines*

IBC Review	IACUC Review
<ul style="list-style-type: none">▪ Risks to human health<ul style="list-style-type: none">□ Transfer of genetically altered material, viral vectors etc.▪ Risks to the environment<ul style="list-style-type: none">□ Escape and establishment in the wild□ Interbreeding with wild stock□ Consumption by other animals	<ul style="list-style-type: none">▪ Animal welfare<ul style="list-style-type: none">□ Pain and distress from adverse phenotypes (behavioral, anatomical and physiological abnormalities)□ Risks to other animals in the facility from the inadvertent spread of vectors



IBCs and NIH OBA

- NIH OBA provides oversight, guidance, and resources for IBCs
 - Staff and information resources available to help ensure IBCs, their institutions, and investigators are compliant with the *NIH Guidelines*
 - Scientific and medical staff available to answer queries
 - Interpretation of *NIH Guidelines*
 - Containment
 - Exemptions
 - Risk group classification
- **If local expertise is not available, the IBC can ask the NIH OBA**



How to Apply to CSU IBC

<https://csuohio.edu/sprs/ibc>

General Info & Resources

- » FAQs
- » SPRS Forms
- » Our Services
- » Monthly Activity Reports
- » Staff Directory

Compliance

- » IRB (Humans)
- » IACUC (Animals)
- » IBC (Biosafety)
- » Equipment Billing Guidance

Mailing Address
Sponsored Programs and



How to Apply to CSU IBC

<https://csuohio.edu/sprs/ibc>

Links to the NIH Guidelines, the Biosafety in Microbiological and Biomedical Laboratories (BMBL) 5th edition, and other biosafety guidance is available under the Links section.

IBC FORMS FOR DOWNLOAD

- [IBC Application Form](#)
- [Examples](#)
- [Application Continuation Pages](#)
 - [S2A Continuation Page](#)
 - [S4C Continuation Page](#)
 - [S5 Continuation Page](#)

IBC REQUIREMENTS

- [Biosafety Level 1 Requirements](#)
- [Biosafety Level 2 Requirements](#)
- [Biosafety cabinets \(BSC\) OSHA requirements](#)
- [Requirements for IBC's PowerPoint](#)

Site will always have current forms!

Application and Examples (SAMPLE TEXT)

Application and process modeled after CWRU (Survived NIH OBA Audit)

What do BSLs mean?




How to Apply to CSU IBC

¶
1C. Application Date¶

5/20/2020¶

¶
1D. Is this a new submission, resubmission, renewal, or amendment? *New submissions are applications that have not been previously submitted. Resubmissions involve applications that have been previously rejected or returned for revision. Renewals allow the project to continue beyond the prior approval period. Amendments update the project when there are changes in personnel or experimental details before a renewal is required.*¶

New Submission ¶



Approvals are good for 3 years, but an amendment should be submitted if there are major changes:

- *New recombinant/synthetic nucleic acids*
- *Adding lentiviral transduction*



How to Apply to CSU IBC

Statement of safety procedures in place:↵

This CRISPR design does package the gRNA and CAS9 enzyme within the same viral particle. In addition to safety protocols designed to prevent exposure (described below), the risk to researchers is mitigated by the exclusive targeting of mouse genes within our mouse oligodendrocyte progenitor cells. Although the targeted genes are conserved between mouse and human, the guides we have chosen show low complementarity to the human homolog sequence (and other human genomic sequences) as indicated by BLAST alignment.↵

↵
Numerous administrative controls, engineering controls, and use of proper personal protective equipment support the safety of these proposed experiments.↵

- *Safety procedures, decontamination, PPE, and waste disposal are very important parts of the application.*
- *The IBC needs to understand what you are doing and how you're doing it*
- *Superficial applications will be returned*

How to Apply to CSU IBC

3F. What is the proposed Risk Group/Biosafety Level (BSL)/Animal Biosafety Level (ABSL) for this project:

- Risk Group 1 BSL 1 ABSL 1
- Risk Group 2 BSL 2 ABSL 2
- Risk Group 3 BSL 3 ABSL 3
- ABSL N/A

For more info on Risk Groups/BSLs/ABSLs please refer to the Biosafety in Microbiological and Biomedical Laboratories (BMBL) at the following link:

<https://www.cdc.gov/labs/pdf/CDC-BiosafetyMicrobiologicalBiomedicalLaboratories-2009-P.PDF>

Reference pages 10, 24 and 61.

- *The PI may propose a suitable Risk Group and Biosafety Level*
- *The IBC will make the final determination of Risk Group and containment*



How to Apply to CSU IBC

- *Completed applications should be emailed (along with any continuation pages, maps of viral vectors, etc) to:*

biosafetycommittee@csuohio.edu

- *Upon receipt, the application will be assigned to an IBC member for review and an IBC meeting will be scheduled*
- *IBCs CANNOT review proposals by email*
- *IBC is currently meeting “as needed”*



Who must apply to IBC?

- The *NIH Guidelines* are applicable to:
“*Research that is conducted at or sponsored by an institution that receives any support for recombinant or synthetic nucleic acid research from NIH*”
- All research at CSU must comply with the *NIH Guidelines*, regardless of funding source
- All research must be approved by IBC unless exempt under the *NIH Guidelines*



When is approval required?

- The *NIH Guidelines* specify three classes of experiments:
 1. Experiments that must have IBC approval before initiation (RG \geq 2 vector, DNA from RG \geq 2 organism cloned into host-vector system, some whole animals or plants, >10L of culture, etc.)
 2. Experiments that require IBC notice simultaneous with initiation (BL1 containment, some whole rodents)
 3. Exempt experiments



What research is exempt?

- Exemptions are listed in *Guidelines* Section III-F and Appendix C:
 - Nucleic acids that cannot replicate (oligos, miRNAs, siRNAs not expressed from plasmid)
 - Recombinant or synthetic nucleic acids in tissue culture
 - *E. coli* K12 host-vector systems (not BL21!)
 - *Saccharomyces* host-vector systems
 - Some exceptions: cloning \geq RG3 DNA, >10L cultures, >1/2 viral genome, etc.



Exemptions for Rodents

- Exemptions are listed in *Guidelines* Section III-F and Appendix C:
 - Purchase, transfer, or breeding of transgenic rodents (< ½ genome from single viral family)
 - If creating new transgenic mouse *at CSU*, IBC must approve before initiation
 - CSU IBC does not need to approve creation of a new transgenic mouse by a company or a collaborator at another institution (just notify IBC by email)



Non-exempt Rodent Work:

- Creating a new transgenic mouse *at CSU*
- Injecting a mouse with virus (recombinant or wild type)
- Introducing recombinant cell lines cell lines into mice (xenografts)

Questions?

